TR

Trestle Biotherapeutics

YC W21

San Diego, US · Founded 2020 · 2 employees · 1 known investors

trestlebio.com ↗

Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.

Founders & leadership· Y Combinator alumni (W21)

Ben ShepherdinFounder

Alice CheninFounder

BS

Ben Shepherd, PhDCEO

AC

Alice Chen, PhD

Investors · 1

Y

Y Combinator✓ verifiedMountain View · $500K – $500K